Health care giant Johnson & Johnson reportedly is close to buying biopharmaceutical company Pharmacyclics, its longtime partner in developing blood cancer treatment Imbruvica.
London's Financial Times reports "people familiar with the matter" say Johnson & Johnson's anticipated offer would value Pharmacyclics of Sunnyvale, California, above its current $17 billion market capitalization. Those sources said a deal could be announced within days but might unravel.
J&J spokeswoman Amy Meyer declined to comment.
Pharmacyclics shares surged on the rumor, jumping 6.3 percent in regular trading and another 3 percent after hours to $237.48.
Johnson & Johnson, based in New Brunswick, New Jersey, usually makes mid-sized acquisitions worth several billion dollars, but paid $21.3 billion in 2011 for Synthes, a Swiss maker of orthopedic surgical equipment. J&J has annual revenue of $74 billion.